Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors

Patent metadata

Field	Value
Publication number	US-9273064-B2
Application number	US-201414586681-A
Country	US
Kind code	B2
Filing date	Dec 30, 2014
Priority date	Jun 24, 2010
Publication date	Mar 1, 2016
Grant date	Mar 1, 2016

Abstract

Compounds of the general formula I

wherein

each of m and n is independently 0 or 1;

R 1 and R 2 , together with the carbon atom to which they are attached, form a heterocyclic ring comprising one or two heteroatoms selected from oxygen, sulfur, —S(O)— and —S(O) 2 —;

R 3 is —CHF 2 , —CF 3 , —OCHF 2 , —OCF 3 , —SCHF 2 or —SCF 3 ;

X is a bond, —CH 2 —, or —NH—;

A is aryl, cycloalkyl, cycloalkenyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkenyl, optionally substituted with one or more, same or different substituents selected from R 4 ; and

R 4 is hydrogen, amino, thioxo, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, halogen, oxo, thia, or hydroxy;

or pharmaceutically acceptable salts, hydrates or solvates thereof,

have been found to exhibit PDE4 inhibiting activity, and may therefore be useful in the treatment of inflammatory diseases and disorders.

First claim

The invention claimed is:

1. A method of treating or dermal diseases or conditions, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula IIb, optionally together with a pharmaceutically acceptable carrier or one or more excipients, wherein the dermal diseases or conditions are selected from the group consisting psoriasis, acne, and atopic dermatitis,

wherein
each of m and n is independently 0 or 1;
R 1 and R 2 , together with the carbon atom to which they are attached, form a heterocyclic ring comprising one or two heteroatoms selected from oxygen, sulfur, —S(O)— and —S(O) 2 —; and
R3 is —OCHF 2 , or —OCF 3 ;
or a pharmaceutically acceptable salt, hydrate or solvate thereof.

2. The method of claim 1 , wherein the compound of formula IIb is 2-(3,5-dichloro-1-oxido-pyridin-4-yl)-1-{9-difluoromethoxy-spiro[2H-1,5-benzodioxepin-3 (4H),3′-oxetane]-6-yl}ethanone (compound 102).

3. The method of claim 1 , wherein the compound of formula IIb is 2-(3,5-dichloro-1-oxido-pyridin-4-yl)-1-{9-difluoromethoxy-spiro[2H-1,5-benzodioxepin-3(4H),4′-tetrahydropyran]-6-yl}ethanone (compound 104).

4. The method of claim 1 , wherein the compound of formula IIb, is 2-(3,5-dichloro-1-oxido-pyridine-4-yl)-1-(7-difluoromethoxy-2′,3′,5′,6′-tetrahydro-spiro[1,3-benzodioxole-2,4′-(4H)-pyran]-4-yl)ethanone (compound 106).

5. The method of claim 1 , wherein the compound of formula IIb is 2-(3,5-dichloro-1-oxido-pyridine-4-yl)-1-(7-difluoromethoxy-2′,3′,5′,6′-tetrahydro-spiro[1,3-benzodioxole-2,4′-(4H)-thiopyran-1′,1′-dioxide]-4-yl)ethanone (compound 108).

6. The method of claim 2 , wherein the dermal disease or condition is selected from the group consisting of psoriasis and atopic dermatitis.

7. The method of claim 3 , wherein the dermal disease or condition is selected from the group consisting of psoriasis and atopic dermatitis.

8. The method of claim 4 , wherein the dermal disease or condition is selected from the group consisting of psoriasis and atopic dermatitis.

9. The method of claim 5 , wherein the dermal disease or condition is selected from the group consisting of psoriasis and atopic dermatitis.

10. The method of claim 1 , wherein the compound is administered by the oral route.

11. The method of claim 2 , wherein the compound is administered by the oral route.

12. The method of claim 3 , wherein the compound is administered by the oral route.

13. The method of claim 4 , wherein the compound is administered by the oral route.

14. The method of claim 5 , wherein the compound is administered by the oral route.

15. The method of claim 6 , wherein the compound is administered by the oral route.

16. The method of claim 7 , wherein the compound is administered by the oral route.

17. The method of claim 8 , wherein the compound is administered by the oral route.

18. The method of claim 9 , wherein the compound is administered by the oral route.

19. The method of claim 1 , wherein atopic dermatitis is selected from the group consisting of pruritis and eczema.

Assignees

• Leo Pharma As

Inventors

• Nielsen Simon Feldbaek

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title